Robert A. Kyle

117.1k total citations · 20 hit papers
1.0k papers, 59.9k citations indexed

About

Robert A. Kyle is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Robert A. Kyle has authored 1.0k papers receiving a total of 59.9k indexed citations (citations by other indexed papers that have themselves been cited), including 491 papers in Molecular Biology, 474 papers in Hematology and 212 papers in Genetics. Recurrent topics in Robert A. Kyle's work include Multiple Myeloma Research and Treatments (437 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (289 papers) and Chronic Lymphocytic Leukemia Research (150 papers). Robert A. Kyle is often cited by papers focused on Multiple Myeloma Research and Treatments (437 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (289 papers) and Chronic Lymphocytic Leukemia Research (150 papers). Robert A. Kyle collaborates with scholars based in United States, United Kingdom and Canada. Robert A. Kyle's co-authors include S. Vincent Rajkumar, Morie A. Gertz, Angela Dispenzieri, Philip R. Greipp, Martha Q. Lacy, John A. Lust, Shaji Kumar, Terry M. Therneau, Dirk R. Larson and Rafaël Fonseca and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Robert A. Kyle

953 papers receiving 57.7k citations

Hit Papers

International Staging System for Mult... 1978 2026 1994 2010 2005 2007 2003 2004 2002 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. International Staging System for Multiple Myeloma
    2005 1.9k citations Philip R. Greipp, Bart Barlogie et al. Journal of Clinical Oncology profile →
  2. Improved survival in multiple myeloma and the impact of novel therapies
    2007 1.7k citations Shaji Kumar, S. Vincent Rajkumar et al. Blood profile →
  3. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
    2003 1.6k citations Robert A. Kyle, Morie A. Gertz et al. Mayo Clinic Proceedings profile →
  4. Multiple Myeloma
    2004 1.0k citations Robert A. Kyle, S. Vincent Rajkumar New England Journal of Medicine profile →
  5. A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
    2002 969 citations Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine profile →
  6. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
    2013 957 citations Shaji Kumar, Angela Dispenzieri et al. profile →
  7. Prevalence of Monoclonal Gammopathy of Undetermined Significance
    2006 899 citations Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine profile →
  8. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
    2008 800 citations Robert A. Kyle, S. Vincent Rajkumar profile →
  9. Multiple myeloma
    2017 755 citations Shaji Kumar, S. Vincent Rajkumar et al. profile →
  10. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
    2009 743 citations Ola Landgren, Robert A. Kyle et al. Blood profile →
  11. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
    2012 730 citations Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology profile →
  12. Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
    2004 639 citations Angela Dispenzieri, Morie A. Gertz et al. Journal of Clinical Oncology profile →
  13. Multiple myeloma
    2008 638 citations Robert A. Kyle, S. Vincent Rajkumar Blood profile →
  14. Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
    2007 580 citations Robert A. Kyle, Terry M. Therneau et al. New England Journal of Medicine profile →
  15. Increased Prevalence and Mortality in Undiagnosed Celiac Disease
    2009 555 citations Robert A. Kyle et al. profile →
  16. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
    2002 478 citations Jerry A. Katzmann, Raynell Clark et al. profile →
  17. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System
    2016 475 citations Robert A. Kyle, Steven R. Zeldenrust et al. profile →
  18. Monoclonal gammopathy of undetermined significance
    1978 454 citations Robert A. Kyle profile →
  19. Amyloidosis (AL). Clinical and laboratory features in 229 cases.
    1983 449 citations Robert A. Kyle, Philip R. Greipp profile →
  20. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
    2018 351 citations Robert A. Kyle, Dirk R. Larson et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert A. Kyle United States 125 35.1k 34.0k 19.2k 12.5k 5.5k 1.0k 59.9k
Kenneth C. Anderson United States 139 47.4k 1.3× 42.0k 1.2× 30.5k 1.6× 7.8k 0.6× 7.5k 1.3× 1.4k 76.9k
Thomas E. Witzig United States 101 11.2k 0.3× 9.6k 0.3× 13.5k 0.7× 8.6k 0.7× 14.1k 2.6× 778 34.1k
Bart Barlogie United States 109 24.5k 0.7× 30.7k 0.9× 18.3k 1.0× 5.7k 0.5× 3.4k 0.6× 704 42.4k
Jesús F. San Miguel Spain 95 19.1k 0.5× 28.1k 0.8× 14.8k 0.8× 8.0k 0.6× 4.8k 0.9× 1.0k 40.3k
Benjamin L. Ebert United States 78 46.7k 1.3× 14.2k 0.4× 10.7k 0.6× 9.0k 0.7× 3.2k 0.6× 294 73.5k
Anthony D. Ho Germany 77 9.6k 0.3× 7.6k 0.2× 7.5k 0.4× 8.0k 0.6× 4.4k 0.8× 687 27.5k
Pier Paolo Pandolfi United States 139 61.9k 1.8× 8.1k 0.2× 13.1k 0.7× 3.6k 0.3× 3.2k 0.6× 449 80.3k
Alessandro Rambaldi Italy 83 8.1k 0.2× 9.6k 0.3× 5.6k 0.3× 8.5k 0.7× 4.7k 0.8× 661 24.3k
Raghu Kalluri United States 120 49.4k 1.4× 1.9k 0.1× 21.0k 1.1× 4.3k 0.3× 3.5k 0.6× 321 83.3k
Ayalew Tefferi United States 115 22.2k 0.6× 34.8k 1.0× 4.6k 0.2× 38.2k 3.0× 3.6k 0.7× 1.1k 54.7k

Countries citing papers authored by Robert A. Kyle

Since Specialization
Citations

This map shows the geographic impact of Robert A. Kyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Kyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Kyle more than expected).

Fields of papers citing papers by Robert A. Kyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Kyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Kyle. The network helps show where Robert A. Kyle may publish in the future.

Co-authorship network of co-authors of Robert A. Kyle

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Kyle. A scholar is included among the top collaborators of Robert A. Kyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Kyle. Robert A. Kyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anderson, Larry D., Joan Bladé, & Robert A. Kyle. (2024). A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow‐up. SHILAP Revista de lepidopterología. 5(1). 235–237. 1 indexed citations
2.
Visram, Alissa, Camilia Soof, S. Vincent Rajkumar, et al.. (2021). Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer Journal. 11(6). 120–120. 33 indexed citations
3.
Afshar, Ahmadreza, Robert A. Kyle, & David P. Steensma. (2017). Adolf Lorenz – The Bloodless Surgeon of Vienna. Mayo Clinic Proceedings. 92(7). e105–e106. 1 indexed citations
4.
Steensma, David P., Daniel Rayson, Marc A. Shampo, & Robert A. Kyle. (2014). Terry Fox: Canadian Cancer Research Activist Whose “Marathon of Hope” Inspired Millions. Mayo Clinic Proceedings. 89(8). e75–e76. 3 indexed citations
5.
Kapoor, Prashant, Shaji Kumar, Angela Dispenzieri, et al.. (2013). Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma. Journal of Clinical Oncology. 31(36). 4529–4535. 120 indexed citations
6.
Wadhera, Rishi K., Robert A. Kyle, Dirk R. Larson, et al.. (2011). Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 118(11). 2985–2987. 29 indexed citations
7.
Landgren, Ola, James J. Goedert, Charles S. Rabkin, et al.. (2010). Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. Journal of Clinical Oncology. 28(5). 773–779. 80 indexed citations
8.
Kumar, Shaji, Angela Dispenzieri, Jerry A. Katzmann, et al.. (2010). Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 116(24). 5126–5129. 121 indexed citations
9.
Lacy, Martha Q., Suzanne R. Hayman, Morie A. Gertz, et al.. (2009). Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology. 27(30). 5008–5014. 226 indexed citations
10.
Morel, Pierre, Alain Duhamel, Paolo G. Gobbi, et al.. (2009). International prognostic scoring system for Waldenström macroglobulinemia. Blood. 113(18). 4163–4170. 228 indexed citations
11.
Vachon, Celine M., Robert A. Kyle, Terry M. Therneau, et al.. (2009). Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 114(4). 785–790. 87 indexed citations
12.
Landgren, Ola, Robert A. Kyle, Ruth M. Pfeiffer, et al.. (2009). Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood. 113(22). 5412–5417. 743 indexed citations breakdown →
13.
Thompson, Carrie A., Robert A. Kyle, Morie A. Gertz, et al.. (2009). Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients. American Journal of Hematology. 85(3). 171–173. 54 indexed citations
14.
Chng, Wee Joo, Shaji Kumar, Scott VanWier, et al.. (2007). Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling. Cancer Research. 67(7). 2982–2989. 195 indexed citations
15.
Dispenzieri, Angela, Robert A. Kyle, Jerry A. Katzmann, et al.. (2007). Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 111(2). 785–789. 285 indexed citations
16.
Kyle, Robert A., Terry M. Therneau, S. Vincent Rajkumar, et al.. (2006). Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine. 354(13). 1362–1369. 899 indexed citations breakdown →
17.
Zhu, Xueyong, Paul Wentworth, Robert A. Kyle, Richard A. Lerner, & Ian A. Wilson. (2006). Cofactor-containing antibodies: Crystal structure of the original yellow antibody. Proceedings of the National Academy of Sciences. 103(10). 3581–3585. 26 indexed citations
18.
Kyle, Robert A., Terry M. Therneau, S. Vincent Rajkumar, et al.. (2002). A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine. 346(8). 564–569. 969 indexed citations breakdown →
19.
Gertz, Morie A., Robert A. Kyle, & Pierre Noël. (1993). Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.. Journal of Clinical Oncology. 11(5). 914–920. 108 indexed citations
20.
Kyle, Robert A.. (1975). Multiple Myeloma: Review of 869 Cases. Mayo Clinic Proceedings. 50(1). 29–40. 99 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth C. Anderson Breakdown of academic impact, for papers by Thomas E. Witzig Breakdown of academic impact, for papers by Bart Barlogie Breakdown of academic impact, for papers by Jesús F. San Miguel Breakdown of academic impact, for papers by Benjamin L. Ebert Breakdown of academic impact, for papers by Anthony D. Ho Breakdown of academic impact, for papers by Pier Paolo Pandolfi Breakdown of academic impact, for papers by Alessandro Rambaldi Breakdown of academic impact, for papers by Raghu Kalluri Breakdown of academic impact, for papers by Ayalew Tefferi
Rankless by CCL
2026